Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29567277 | 1.00 | PGR (0.42) | PGRKDM1AMAOAFSCN1TSHR | |
| SCHEMBL24309603 | 0.91 | POLB (0.45) | PGRTSHRSMN1; SMN2POLBPKM | |
| SCHEMBL26807167 | 0.89 | MAPT (0.45) | PGRTSHRSMN1; SMN2POLBPKM | |
| SCHEMBL26806771 | 0.88 | PGR (0.41) | PGRKDM1AMAOAFSCN1POLB | |
| SCHEMBL29702903 | 0.86 | ALDH1A1 (0.43) | TSHRSMN1; SMN2POLBCCR2 | |
| SCHEMBL24330515 | 0.86 | ALDH1A1 (0.43) | TSHRSMN1; SMN2POLBCCR2 | |
| SCHEMBL29566688 | 0.86 | SMN1; SMN2 (0.40) | KDM1ATSHRSMN1; SMN2POLBPKM | |
| SCHEMBL24310577 | 0.86 | SMN1; SMN2 (0.40) | KDM1ATSHRSMN1; SMN2POLBPKM | |
| SCHEMBL26807163 | 0.86 | SMN1; SMN2 (0.40) | TSHRSMN1; SMN2POLBPKMMAPT | |
| SCHEMBL24309642 | 0.85 | POLB (0.43) | KDM1ATSHRSMN1; SMN2POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | PGR 4116/4885KDM1A 4709/4885MAOA 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.